Dispensys AG has been acquired by Sulzer Mixpac AG
The owner of Dispensys AG has sold the company to Sulzer Mixpac AG. Financial details of this transaction have not been disclosed.
Dispensys develops and produces dispensers and cartridges for every 2-component application in the dental market such as for impression materials, temporary crown and bridge materials, cements, bleaching products and others. The owner of Dispensys wanted to focus on the development of new products.
Sulzer Mixpac is the world’s leading manufacturer and supplier of metering, mixing and dispensing systems and disposable mixers for reactive multicomponent materials.
Oaklins' team in Switzerland acted as the exclusive financial advisor to the seller.
Talk to the deal team
Related deals
Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn moreEuroHospital Varna has been acquired by Intermedica Group
EuroHospital Varna has been acquired by Intermedica Group, allowing the business to continue to grow and deliver high-quality healthcare services to its patients. Through the transaction, Intermedica Group expands its healthcare presence and intends to build a new model of integrated personalized care focused on preventive, holistic and digital medicine.
Learn moreOlyos Group has acquired a controlling stake in NewScience
Olyos Group has acquired a controlling stake in NewScience from its founders through a transaction structured in two stages, with the strategic objective of ultimately acquiring 100% of the company. The transaction forms part of NewScience’s international growth strategy and a gradual cash-out process for the founder, who intends to complete a full exit. Olyos intends to retain the management team through a put and call option mechanism and an earn-out linked to NewScience’s 2025 EBITDA.
Learn more